Peripheral Perfusion Index As an Early Predictor of Successful Caudal Block in Pediatric Patients Undergoing Lower Abdominopelvic Surgeries Under General Anesthesia
Launched by AIN SHAMS UNIVERSITY · Feb 21, 2025
Trial Information
Current as of October 30, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how the Peripheral Perfusion Index (PPI) can help predict whether a specific type of pain relief called a caudal block will be successful in young children undergoing lower abdominal surgeries. The trial is currently looking for children aged 1 to 5 years who are scheduled for planned surgeries that last less than two hours. To participate, children should be generally healthy (classified as ASA I or II), meaning they have no serious health issues.
If your child is eligible and you choose to participate, they will be monitored to see how well the PPI can indicate the success of the caudal block, which is given to help manage pain during and after surgery. It's important to note that children with certain health conditions, such as infections at the injection site or serious neurological disorders, will not be eligible for this study. By participating, you could help contribute to important research that aims to improve pain management practices for young patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients aging between 1-5 years of both sexes.
- • Pediatric patients posted for elective lower abdominopelvic surgeries under general anesthesia (duration of surgery under 120 minutes).
- • ASA physical status classes I - II.
- Exclusion Criteria:
- • Guardian's refusal of procedure or participation in the study.
- • ASA classes III or above.
- • Infection at site of injection.
- • Neurological diseases and disorders such as (neuromuscular disease, cerebral palsy, spinal dysraphism ...etc.)
- • Coagulopathy and bleeding disorders.
- • Hypersensitivity to the study medications.
- • Patients receiving vasoactive drugs or beta blockers.
- • Patients undergoing emergency surgery.
- • Patients in active clinical sepsis.
About Ain Shams University
Ain Shams University, established in Cairo, Egypt, is a prestigious higher education institution renowned for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise in various medical and scientific disciplines to advance healthcare through rigorous research initiatives. With a focus on ethical practices and adherence to regulatory standards, Ain Shams University aims to contribute to the development of new therapies and improve patient outcomes, fostering collaboration among researchers, healthcare professionals, and industry partners in the pursuit of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Abbasia, Egypt
Patients applied
Trial Officials
Omar Mohamed Taha Abdallah El-Safty, M.B.B.CH., MD.
Study Chair
Faculty of Medicine, Ain Shams University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported